Guides15 min readAugust 8, 2026

GLP-1 Provider Comparison: The Five Things That Actually Separate Them

We have reviewed 195 GLP-1 providers. Price barely predicts quality. These five differences do — and each one is something you can check before you pay anything.

By Med Consumer Watch Team

We have now reviewed 195 companies selling semaglutide and tirzepatide — national telehealth platforms, manufacturer pharmacies, men's health chains, med spas, compounding pharmacies and single-clinic practices in eight metro markets. The clearest finding is that price predicts almost nothing. We found $99 programs that name their pharmacy and $699 programs that will not, $49 behavioural support that outperforms $299 "coaching," and one $120-a-month clinic offering both genuine physician oversight and a drug the FDA says does not work for weight loss. Five differences do predict quality. Each is checkable before you spend anything, and each one sorts the field fast. 1. Who evaluates you, and can they say no? 2. What is actually in the vial? 3. Where is the eligibility bar set? 4. How does the billing really work? 5. What do they decline to publish? Here is what each looks like at the good end and the bad end, with names.

1. Who evaluates you — and can they say no?

The strongest single predictor we found is whether a company has any mechanism for declining to treat you, and whether it says so in public. The good end. Heyday Health requires comprehensive labs before prescribing anything and states plainly: "If your labs don't indicate clinical low testosterone, or if there are contraindications, we won't prescribe it." TelePeptide holds your card at intake but bills nothing at all if a clinician does not prescribe — removing the fee that would otherwise reward approving everyone. Clinic Concierge states in advance that GLP-1s will not suit every patient. Credentials matter too. TOM Weight Loss staffs board-certified obesity medicine physicians — a recognised subspecialty, and a credential almost nobody else in our set claims. MD Total Wellness names two clinicians who have practised together since 2006, first in bariatric surgery. The weak end is the questionnaire-to-checkout flow: a form, an unnamed reviewer, a prescription. Several companies describe "licensed providers" without ever saying whether that means a physician, nurse practitioner or physician assistant. Heyday is unusual in stating outright that its prescribers are NPs or PAs with a collaborating physician of record — disclosure, not evasion.

Ask directly: “Under what circumstances would you decline to prescribe for me?” A company with a real answer has a real screen. A company that cannot think of one is selling, not treating.

2. What is actually in the vial?

This is the difference that changed most in 2026, and most marketing has not caught up. Manufacturer-direct is now genuinely competitive. LillyDirect sells FDA-approved Zepbound self-pay at $299 (2.5 mg) to $699 (10–15 mg), and lists Foundayo (orforglipron), Lilly's oral GLP-1, from $149. NovoCare Pharmacy sells Wegovy at $199 for the pen, $149 for the tablet, or as little as $25/month with commercial insurance. Eligible Medicare Part D patients may pay no more than $50/month for Zepbound through the Medicare GLP-1 Bridge. Compounded programs in our reviews run $89 to $499. The gap that once justified compounding has largely closed. Some providers route you to the approved product. The Virtual NP states that after approval you pay for "the FDA-approved medication from Eli Lilly or Novo Nordisk." Clinical Nutrition Center names Zepbound and Wegovy and navigates prior authorization for you. Some blur it. TeleHealthNP advertises brand-name Ozempic and Zepbound while its published plan sells a "2 mL GLP-1" — a presentation characteristic of compounded multi-dose vials, not brand-name pens. EllieMD markets by mechanism only — "GLP-1 Oral Drops," "GLP-1/GIP Injection" — so a patient cannot tell which molecule they are getting. And a whole category has no evidence at all. Sublingual drops, rapid-dissolve tablets, and — at The Wellness Company — tirzepatide chewing gum. For tirzepatide this is sharper than for semaglutide: there is no FDA-approved oral tirzepatide in any form, so there is not even a reference product. Every published tirzepatide result comes from a weekly injection.

Option | Typical monthly cost | FDA-approved | Pharmacy knowable
Commercial insurance copay (Wegovy) | as low as $25 | Yes | Yes
Medicare GLP-1 Bridge (Zepbound) | ~$50 | Yes | Yes
NovoCare Wegovy tablet / pen | $149 / $199 | Yes | Yes
LillyDirect Zepbound | $299–$699 | Yes | Yes
Compounded telehealth | $89–$499 | No | Usually not
Compounded sublingual / oral | varies | No | Usually not

If you cannot inject, buy the FDA-approved oral semaglutide from NovoCare at $149 rather than a compounded sublingual drop. The approved product uses a purpose-built absorption enhancer that a compounded preparation does not replicate, and no published trial establishes what dose reaches the bloodstream from a compounded sublingual.

3. Where is the eligibility bar set?

The approved indication is BMI 30 or above, or 27 or above with a weight-related condition. How far a company drops below that tells you what it is optimising for. Held at the real line. Setpoint Wellness, a two-clinic practice in Folsom, publishes exactly the FDA criteria and names the qualifying comorbidities. Garcia Weight Loss in Tampa does the same, naming type 2 diabetes and hypertension. Both are small practices choosing a stricter gate than national competitors — which costs them volume. Dropped well below. EllieMD publishes a three-tier floor: BMI 25 for new patients, 22 for transfers, and 20 for microdosing. WeightCare opens microdosing at BMI 20. A BMI of 20 is inside the normal healthy range. Prescribing an appetite-suppressing medication to someone at a healthy weight is a different proposition from treating obesity, and "microdosing" compounds it — sub-therapeutic doses were not what any trial studied. Watch the wide gate too. Gameday Men's Health states that "most men experiencing low energy, reduced performance, low libido, weight challenges, or hormone imbalance symptoms qualify." A program expecting most enquirers to qualify is describing a funnel, not a screen.

4. How does the billing really work?

Three billing structures cost real money and are easy to miss. The 28-day cycle. iThriveMD states that "all memberships will be charged every 28 days." That is 13.04 charges a year, not 12 — turning an apparent $299/month into roughly $3,900 a year instead of $3,588. TeleHealthNP bills $299 every 4 weeks with the same effect. Both disclose it; neither converts it for you. Dose-escalation pricing. GLP-1 doses titrate upward over months. Programs that charge by dose raise your cost precisely as you reach the doses that produced the trial results — a structure that quietly rewards staying underdosed. 61Five publishes four tiers at $80, $100, $140 and $160 per weekly injection; at the top that is roughly $694 a month, against LillyDirect's $699 for approved Zepbound. Two companies refuse to do this from opposite ends of the market: Trimi at $99–$125/month and Rivas at $115–$165/week both hold price flat across every dose. Per-week and per-injection framing. $115 a week reads small. It is about $498 a month. Always convert before comparing.

Structure | What it looks like | What it actually costs
28-day billing | “$299/month” | ~$3,900/yr, not $3,588
Per-injection pricing | “$160 per shot” | ~$694/month
Per-week pricing | “$115/week” | ~$498/month
Dose-tier pricing | cheap at 2.5 mg | rises as you titrate up
Flat pricing | same at every dose | no penalty for therapeutic dosing

Before enrolling anywhere, ask for the total annual cost at the dose you expect to be maintained on — not the starting dose, and not the first-month promotional rate.

5. What do they decline to publish?

Absence is evidence. Across 195 reviews, the same five omissions recur — and the companies that fill them in are consistently the better ones. Pricing. Roughly half the providers we reviewed publish none at all. Compare TelePeptide, which states "no quote forms, no 'contact sales' — every program, every tier, every price is published," against TelehealthFx, which advertises "100% transparent pricing" while publishing no prices we could find. The pharmacy. Covered in our compounding pharmacy guide — this is the most common gap of all. Eligibility criteria. Many companies say they will confirm you "qualify" without publishing against what standard. Trial-figure attribution. The correct form names the branded product the data came from. Form Blends writes the clearest version we found: figures are from trials of "the FDA-approved branded medications (Wegovy, Zepbound), combined with diet and exercise… not outcomes for compounded products, for FormBlends specifically, or for any individual patient." Trimi footnotes this correctly but still places "Up to 22% weight loss" beside "Compounded Tirzepatide." And the outright false claim. EllieMD advertises losing "up to 26%+ of initial body weight over 6-8 weeks." No trial supports it — the best result in the class is about 20.9% over 72 weeks — and EllieMD's own FAQ calls 1–2 lb per week the safe rate, which is 4–8% over the same eight weeks. Both statements are on its website.

Two claims should end your consideration of a provider outright: a weight-loss figure no trial supports, and a drug the FDA has said does not work. Saguaro Medical Weight Control lists HCG on the same prescribing menu as semaglutide — FDA regulations require HCG labelling to state there is no substantial evidence it increases weight loss beyond calorie restriction alone.

The half nobody sells you

One pattern deserves its own section, because it is the most consequential thing we found and almost no medication vendor addresses it. The trials paired medication with lifestyle intervention throughout. STEP and SURMOUNT participants received structured support alongside the drug. Most commercial programs sell only the drug, then call whatever remains "coaching" delivered by unspecified staff. Two problems follow, and neither is solved by a higher dose: Lean mass. Weight lost on a GLP-1 includes muscle, and appetite suppression makes adequate protein intake harder at exactly the point it matters most. Regain. Weight returns substantially after discontinuation. What carries over is the behaviour built during treatment. Three companies address this properly. Nourish connects patients to registered dietitians in all 50 states, billed to insurance — it reports 94% of patients pay $0, with 50–60 minute sessions weekly or biweekly. The Mayo Clinic Diet runs a 24-week GLP-1 track with a protein-focused meal plan for $49.99/month. Macros Inc states plainly that GLP-1 weight loss takes muscle and that many users regain after stopping — and organises around the off-ramp. None of the three prescribes anything. That is the point: pair one of them with a prescriber, ideally one dispensing FDA-approved product.

If your program includes “coaching,” ask one question: what credential does the coach hold? Nourish and the Mayo Clinic Diet answer “registered dietitian.” Many others do not answer at all.

Putting it together

You do not need to run all five checks on twenty companies. Run them in order and the field collapses quickly. Start with price the approved product. If Wegovy is $25 with your insurance, or $149 as a tablet, or Zepbound is $50 on the Medicare Bridge, most of this comparison stops being relevant. If compounded still makes sense for you, require a named pharmacy, published pricing at your maintenance dose, an eligibility standard you recognise, and flat or clearly-stated billing. Then add the half that is not medication — a registered dietitian, billed to insurance if you can.

Check | Best in our reviews | Worst pattern
Can they say no | Heyday, TelePeptide | questionnaire to checkout
What is in the vial | LillyDirect, NovoCare | unnamed “GLP-1”, sublingual, gum
Eligibility bar | Setpoint, Garcia | BMI 20 microdosing
Billing clarity | Trimi, Rivas | 28-day cycles, dose tiers
What they publish | Form Blends, Pure Pharmacy | 26% in 6–8 weeks

The Bottom Line

The single most useful thing we can tell you after 195 reviews is that the expensive option is not reliably the good one, and the cheap option is not reliably the bad one. Saguaro offers real physician oversight at $120 a month and lists a drug that does not work. EllieMD has a named 503A partner, batch testing and no hidden fees — attached to a weight-loss claim its own safety guidance contradicts. What separates providers is not what they charge. It is whether they will tell you who prescribes, what is in the vial, who qualifies, what you will actually be billed, and what the evidence does not show. Every one of those is answerable before you pay. Ask all five. The companies worth using answer readily — several publish the answers without being asked. This article is general information, not medical advice. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or manufacturing quality. GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumours and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Prices cited were published by the companies named as of August 8, 2026 and change frequently. Always consult your own physician before starting, changing or stopping any medication.

Sources & References

Medical Disclaimer

This article is for informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making decisions about your health or medications. Individual experiences may vary.

How to Check a Compounding Pharmacy Before You Buy

Five checks, all free and public, that take about twenty minutes.

Brand-Name vs Compounded GLP-1: What Changed in 2025, and What to Ask Before You Buy

GLP-1 Eligibility: Who Actually Qualifies

The real BMI thresholds, and why some programs ignore them.

Semaglutide vs Tirzepatide: The Head-to-Head Trial Evidence

Back to All Articles

Enter to Win a $1,788 CoreAge Rx Gift Card

Enter for a chance to use it toward eligible CoreAge Rx products and services.

The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.